DNA Dispatch

OGT is pleased to introduce the SureSeq™ Myeloid Fusion Panel, expanding your ability to identify key fusion genes implicated in AML and enhancing the understanding of myeloid cancer classification and progression.

At OGT, we are committed to the developing the highest quality products and are continually expanding our range of CytoCell^® IVDR-certified FISH probes, as such we are delighted to announce the launch of:

• CBFβ (CBFB)/MYH11 Translocation, Dual Fusion Probe
• EVI1 (MECOM) Breakapart Probe
• P53 (TP53)/ATM Combination Deletion Probe

Discover the importance of detecting genetic variations in our CytoSure^® whitepaper!

Highlighting the crucial role of identifying genetic changes, like Copy Number Variation (CNV) and Loss of Heterozygosity (LOH), in studying developmental disorders.

At OGT, we develop pioneering hybridisation technology that fits seamlessly into your workflows.

Leveraging rational, expert-driven development, our SureSeq myeloid range offers enhanced detection of complex structural variants, better coverage uniformity and a clearer genetic profile of your samples.

Dive into our discussion on the development and current state of sequencing technologies, and where the future of NGS may take us.